You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
Brief News on Innovation
Company News Brief News on Innovation
NEW AV21 SPECIFICATION: PEIJIA MEDICAL’S TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) SYSTEM APPROVED BY THE NMPA
2024-04-19 10:58:12

On April 18, 2024, new AV21 specification of TaurusOne® and TaurusElite® TAVR systems, developed by the Company, has been approved by the NMPA. The new specification has the following advantages: 1) Precise fit: specially designed for the smaller aortic root structure of Chinese patients 2) Large EOA: supra-annular valve design; higher radial force; lower risk of PPM 3) Waist design: ensures coronary artery safety 4) Short stent: with a stent height of 40.5mm, it poses a low risk of ascending aorta dissection after implantation.


Top